chr3-123682239-C-T
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 1P and 2B. PP2BP4_Moderate
The NM_053025.4(MYLK):c.3637G>A(p.Val1213Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000247 in 1,601,306 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V1213L) has been classified as Likely benign.
Frequency
Consequence
NM_053025.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYLK | NM_053025.4 | c.3637G>A | p.Val1213Met | missense_variant | 20/34 | ENST00000360304.8 | NP_444253.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYLK | ENST00000360304.8 | c.3637G>A | p.Val1213Met | missense_variant | 20/34 | 5 | NM_053025.4 | ENSP00000353452.3 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152134Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000104 AC: 24AN: 229728Hom.: 0 AF XY: 0.0000894 AC XY: 11AN XY: 123110
GnomAD4 exome AF: 0.000264 AC: 382AN: 1449172Hom.: 0 Cov.: 30 AF XY: 0.000260 AC XY: 187AN XY: 719220
GnomAD4 genome AF: 0.0000920 AC: 14AN: 152134Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74312
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 25, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: 1 proband, no segs in HGMD; ExAC: 5/27770 European chromosomes - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 17, 2023 | Variant summary: MYLK c.3637G>A (p.Val1213Met) results in a conservative amino acid change in the encoded protein sequence. Four of four in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0001 in 230104 control chromosomes (gnomAD and publication data). The observed variant frequency is approximately 42 fold of the estimated maximal expected allele frequency for a pathogenic variant in MYLK causing Aortopathy phenotype (2.5e-06), strongly suggesting that the variant is benign. However, this observance needs to be cautiously considered due to the possibility of the MYLK pseudogene being captured. c.3637G>A has been reported in the literature in individuals affected with thoracic aortic aneurysm/aortic dissection (Wang_2010, Weerakkody_2018). These reports do not provide unequivocal conclusions about association of the variant with Aortopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight ClinVar submitters (evaluation after 2014) cite this variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly benign. - |
Aortic aneurysm, familial thoracic 7 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 1213 of the MYLK protein (p.Val1213Met). This variant is present in population databases (rs368390254, gnomAD 0.02%). This missense change has been observed in individual(s) with thoracic aortic aneurysm or dissection (PMID: 21055718, 29543232). ClinVar contains an entry for this variant (Variation ID: 403212). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MYLK protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 09, 2024 | Has been reported in association with TAAD, though no segregation data are described (PMID: 29543232, 21055718); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29543232, 21055718, 21231930, 29544503) - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Feb 13, 2018 | The MYLK c.3637G>A; p.Val1213Met variant (rs368390254) has been reported in a single family with thoracic aortic aneurysms or aortic dissections (TAAD), but insufficient segregation data was available to determine whether or not the variant is associated with aortic disease (Wang 2010). This variant is listed in the genome Aggregation Database (gnomAD) with an overall population frequency of 0.009% (identified on 23 out of 255,410 chromosomes) and is classified as a variant of unknown significance in ClinVar (ID: 403212). The valine at position 1213 is weakly conserved, considering 12 species, and a methionine is found in this position in several species, suggesting this variant is evolutionarily tolerated. Computational analyses of the effects of the p.Val1213Met variant on protein structure and function do not predict a deleterious effect (SIFT: tolerated, PolyPhen-2: benign). Based on the available information, the clinical significance of the p.Val1213Met variant cannot be determined with certainty. - |
Familial thoracic aortic aneurysm and aortic dissection Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 25, 2021 | The p.V1213M variant (also known as c.3637G>A), located in coding exon 17 of the MYLK gene, results from a G to A substitution at nucleotide position 3637. The valine at codon 1213 is replaced by methionine, an amino acid with highly similar properties, and is located in the actin-binding (calcium/calmodulin-sensitive) domain. This alteration was reported in association with familial thoracic aortic aneurysm and dissection (TAAD) (Wang L et al. Am. J. Hum. Genet., 2010 Nov;87:701-7; Weerakkody R et al. Genet Med, 2018 11;20:1414-1422). This amino acid position is well conserved in available vertebrate species; however, methionine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Atrial septal defect Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital | Nov 11, 2015 | - - |
Aortic aneurysm, familial thoracic 7;C5542316:Megacystis-microcolon-intestinal hypoperistalsis syndrome 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 27, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at